vVARDIS

๐Ÿ“‚ Healthtech๐Ÿ“ Zug๐Ÿ—“๏ธ Founded: 2020

Swiss dental medtech selling dentists Curodont, a peptide-based treatment for early carious lesions.

Europe's most interesting startup stories. Every week.

No spam. Unsubscribe anytime.

Podcast Episode

๐ŸŽ™๏ธ Deep Dive

Nscale, vVARDIS, Kry โ€” IPO scrutiny and digital health consolidation โ€” Daily News November 13, 2026

Listen to the episode

About vVARDIS

vVARDIS is a dental medtech company based in Zug, Switzerland, led by its co-CEOs and founders Haley and Goly Abivardi, both dentists; the holding company was incorporated in 2020. Under the Curodont brand it sells dentists a peptide-based treatment that repairs early carious lesions without drilling or injections: in the US, where Henry Schein has distributed it exclusively since early 2024, the company reports about three million teeth treated and use in nearly 20% of general practices. After $85 million from OrbiMed in 2025, on 27 April 2026 a minority investment by Apollo-managed funds valued it above $1 billion. On 12 November 2026 it priced its NYSE listing (ticker VVVV): 9,722,223 shares at $18, below the initial $21-24 range, for about $175 million gross, with closing expected on 16 November. Revenue for the twelve months to 30 June 2026 was $50 million.

The Story

Founded by dentist sisters Haley and Goly Abivardi; the Swiss holding company was incorporated in 2020.

How vVARDIS works

Business Model

Sales of dental medtech products to professionals through distributors.

Revenue Model

Product sales.

Products & Services

Key Products

  • Curodont Repair Fluoride Plus

Core Use Cases

  • Non-invasive treatment of early cavities

Market & Clients

Key Customers

Dentists and dental practices.

Geographic Presence

CHUS

How vVARDIS competes

Competitive Advantages

  • No drilling or injections
  • Exclusive US distribution with Henry Schein

How vVARDIS grows

Growth Strategy

International commercial expansion, funded partly through the listing.

Distribution Model

B2B sales through dental distributors.

Regulatory Context

Products subject to medical-device approvals in each market; the US offering is subject to SEC rules.

Key Risks

  • Clinical adoption
  • Dependence on one distributor
  • Post-IPO execution

Strategic Insights

  • Pricing below the range shows how selective the IPO market is.
  • The exclusive distribution deal with Henry Schein accelerated US adoption.

Funding & Investors

Latest Valuation

Oltre $1B (investimento Apollo, 27/04/2026) (2026)

Funding Rounds

  • 2026 - Investimento strategico: Non divulgato
    Lead: Apollo
  • 2025 - Funding round: $50M
    Lead: OrbiMed
  • 2025 - Funding round: $35M
    Lead: OrbiMed

Key Investors

ApolloOrbiMed

Founding Team

Founders

Haley AbivardiCo-founder & Co-CEO
Goly AbivardiCo-founder & Co-CEO

Key Metrics

Ricavi ultimi 12 mesi al 30/06/2026$50M (2026)
Denti trattati negli Stati Uniticirca 3 milioni (2026)
Proventi lordi IPOcirca $175M (2026)

Lessons from vVARDIS

  • Access to public markets also depends on the price investors are willing to pay.

Similar Startups

๐Ÿ“ Basilea

Nouscom

A biotech headquartered in Basel with operations in Rome developing viral-vector immunotherapies against tumour neoantigens; its lead candidate is NOUS-209.

Read Analysis
๐Ÿ“ Amsterdam

NewAmsterdam Pharma

Biopharmaceutical company focused on innovative therapies for hypercholesterolemia and cardiometabolic diseases with breakthrough clinical results.

Read Analysis
๐Ÿ“ Lausanne

MindMaze

Founded in Lausanne in 2012, it is now part of the listed group MindMaze Therapeutics (SIX: MMTX) after the December 2025 combination with Relief. It is no longer a private unicorn.

Read Analysis

Sources

๐ŸŽ™๏ธ Scalable Podcast โ€” European startup stories ยท ๐Ÿ‡ฎ๐Ÿ‡น in Italian
Spotify ๐ŸŽง Apple